NNZ-2566 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
156	レット症候群	2
206	脆弱Ｘ症候群	1

156. レット症候群

---

臨床試験数 : 40 /  薬物数 : 53 - (DrugBank : 19) / 標的遺伝子数 : 77 - 標的パスウェイ数 : 113

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02715115 (ClinicalTrials.gov)	March 2016	21/2/2016	A Safety Study of NNZ-2566 in Pediatric Rett Syndrome	A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome	Rett Syndrome	Drug: NNZ-2566;Drug: Placebo	Neuren Pharmaceuticals Limited	rettsyndrome.org	Completed	5 Years	15 Years	Female	82	Phase 2	United States
2	NCT01703533 (ClinicalTrials.gov)	March 2013	4/10/2012	A Safety Study of NNZ-2566 in Patients With Rett Syndrome	A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome	Rett Syndrome	Drug: NNZ-2566;Drug: Placebo	Neuren Pharmaceuticals Limited	Baylor College of Medicine;International Rett Syndrome Foundation	Completed	16 Years	45 Years	Female	67	Phase 2	United States

206. 脆弱Ｘ症候群

---

臨床試験数 : 104 /  薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01894958 (ClinicalTrials.gov)	January 2014	3/7/2013	A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome	A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome	Fragile X Syndrome	Drug: NNZ-2566;Drug: Placebo	Neuren Pharmaceuticals Limited	NULL	Completed	12 Years	45 Years	Male	72	Phase 2	United States